Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Net Margin (2017 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Net Margin for 14 consecutive years, with 19.08% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Margin rose 266.0% year-over-year to 19.08%, compared with a TTM value of 16.73% through Dec 2025, up 224.0%, and an annual FY2025 reading of 16.73%, up 224.0% over the prior year.
  • Net Margin was 19.08% for Q4 2025 at Neurocrine Biosciences, down from 26.36% in the prior quarter.
  • Across five years, Net Margin topped out at 282.0% in Q2 2021 and bottomed at 18.22% in Q1 2023.
  • Average Net Margin over 4 years is 31.76%, with a median of 16.43% recorded in 2024.
  • The sharpest move saw Net Margin surged 25568bps in 2021, then plummeted -1585bps in 2024.
  • Year by year, Net Margin stood at 10.3% in 2021, then skyrocketed by 153bps to 26.03% in 2023, then plummeted by -37bps to 16.43% in 2024, then increased by 16bps to 19.08% in 2025.
  • Business Quant data shows Net Margin for NBIX at 19.08% in Q4 2025, 26.36% in Q3 2025, and 15.64% in Q2 2025.